We believe Eurofins Scientific shares represent compelling value, and we added modestly to our investment in the fourth quarter. Click here to read more.

Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Read why ...

ORION CORPORATION PRESS RELEASE 30 JANUARY 2025 at 16.00 EET Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.